ArticleWorld journal of clinical oncology2025

Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report.

Fei-Fei Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.